Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bexarotene
Drug ID BADD_D00269
Description Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Indications and Usage Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
Marketing Status Prescription
ATC Code L01XF03
DrugBank ID DB00307
KEGG ID D03106
MeSH ID D000077610
PubChem ID 82146
TTD Drug ID D0N0RU
NDC Product Code 0832-0285; 67262-0005; 0054-0399; 48943-0013; 68554-0081; 0187-5525; 69238-1250; 68682-003; 11014-0015; 61474-4298; 11014-0435; 54893-0035; 0187-5526; 10888-8105; 11014-0014; 0378-6955; 14096-150; 43975-315; 69988-0006; 0591-2832; 14593-920
Synonyms Bexarotene | 3-methyl-TTNEB | 4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid | LG69 compound | LGD 1069 | LGD-1069 | LGD1069 | Targretin
Chemical Information
Molecular Formula C24H28O2
CAS Registry Number 153559-49-0
SMILES CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Furuncle23.09.01.004; 11.02.05.008--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gastrooesophageal reflux disease07.02.02.0030.000799%
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Gingivitis07.09.03.003; 11.01.04.013--
Gout15.01.06.001; 14.09.01.001--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoptysis22.02.03.004; 02.01.02.006; 24.07.01.006--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.000533%Not Available
Hepatocellular injury09.01.07.008--Not Available
Herpes simplex23.09.03.001; 11.05.02.001--Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
High density lipoprotein decreased13.12.01.003--Not Available
Hyperaesthesia17.02.06.004--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hypercholesterolaemia14.08.01.0010.000533%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.003--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages